ARNA
Arena Pharmaceuticals, Inc.
Set alert
52-week range unavailable
- Open
- 99.97
- Prev close
- 99.99
- Mkt cap
- 6.17B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 99.97
- High
- 100.00
- Forward P/E
- -13.10
- Beta
- 0.55
- Short ratio
- 5.79
- Inst. own
- 83.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 4, 2022
- 50-d avg
- 93.49
- 200-d avg
- 70.91
- 1y target
- 97.86
Key statistics
- Market cap
- 6.17B
- Enterprise value
- 5.67B
- Trailing P/E
- 0.00
- Forward P/E
- -13.10
- PEG ratio
- 0.00
- Price / sales
- 114172.66
- Price / book
- 9.14
- EPS (TTM)
- -10.14
- Beta
- 0.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 54.00K
- Revenue growth
- 45.90%
- Free cash flow
- -248.32M
- Total cash
- 550.47M
- Total debt
- 51.31M
- Return on equity
- -70.30%
- Shares outstanding
- 61.66M
- Short % of float
- 11.32%
- 50-day average
- 93.49
- 200-day average
- 70.91
Analyst view
Consensus: hold
- Target (low)
- 80.00
- Target (mean)
- 97.86
- Target (high)
- 105.00
- Strong buy2
- Buy2
- Hold3
- Sell0
- Strong sell0
Next earnings
May 4, 2022
Expected May 4, 2022. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 4, 2022 | Mar 1, 2022 | -2.32 | — | — | — |
| Feb 23, 2022 | Dec 1, 2021 | -2.41 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -2.42 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -2.21 | — | — | — |
| May 5, 2021 | Mar 1, 2021 | -2.19 | — | — | — |
| Feb 23, 2021 | Dec 1, 2020 | -1.97 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 9, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 21, 2021 | Cantor Fitzgerald | down | Overweight | Neutral |
| Dec 14, 2021 | Citigroup | down | Buy | Neutral |
| Dec 14, 2021 | JMP Securities | down | Market Outperform | Market Perform |
| Dec 14, 2021 | SVB Leerink | down | Outperform | Market Perform |
| Dec 14, 2021 | RBC Capital | down | Outperform | Sector Perform |
About Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arenapharm.com
News
- Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals
- Pfizer Completes Acquisition of Arena Pharmaceuticals
- 7 Biotech Stocks With Key Catalysts in March
- 11 Marijuana Stocks on Fire to Close February
- Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus
- Earnings Scheduled For February 23, 2022
- Top 3 weed stocks to put on your watch list this year
- Pharma Giants Go After $10 Billion Market With RSV Drugs
- Cannabis Watch: Pfizer's Arena Pharma deal may lead drug company to a cannabis-based treatment
- Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?
Your note
Sign in to keep a note on ARNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AURENTZ VINCENT E | Officer | Stock Award(Grant) | Jan 2, 2022 | 55,122 |
| DALLAS JAYSON DONALD ALEXANDER | Director | Sale | Jun 14, 2021 | 7,152 |
| GALLAHUE KIERAN T. | Director | Stock Award(Grant) | Jun 10, 2021 | 12,911 |
| LISICKI ROBERT | Officer | Stock Award(Grant) | Jan 2, 2022 | 37,563 |
| MANION DOUGLAS J | Officer | Stock Award(Grant) | Jan 2, 2022 | 36,462 |
| MUNSHI AMIT D | Chief Executive Officer | Stock Gift | Mar 7, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Norges Bank Investment Management | 0.92% | 565,956 | 56.59M | Dec 30, 2021 |
| Jefferies Group LLC | 0.20% | 121,719 | 12.17M | Dec 30, 2021 |
| International Biotechnology Trust Plc | 0.03% | 21,000 | 2.10M | Dec 30, 2021 |
| AlphaCentric Advisors LLC | 0.03% | 16,500 | 1.65M | Dec 30, 2021 |
| Amalgamated Bank | 0.01% | 8,251 | 825.02K | Dec 30, 2021 |
| Sphinx Trading, LP | 0.00% | 1,500 | 149.98K | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Global Life Sciences Fund | 0.87% | 536,924 | 53.69M | Dec 30, 2021 |
| Vanguard Explorer Fund, Inc. | 0.85% | 526,953 | 52.69M | Jan 30, 2022 |
| College Retirement Equities Fund-Stock Account | 0.47% | 288,793 | 28.88M | Dec 30, 2021 |
| Primecap Odyssey Aggressive Growth Fund | 0.44% | 271,100 | 27.11M | Jan 30, 2022 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.41% | 251,727 | 25.17M | Feb 27, 2022 |
| Goldman Sachs Small Cap Value Fund | 0.35% | 216,603 | 21.66M | Feb 27, 2022 |